Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Amberly Moreno-Bost"'
Autor:
Tarun K. Garg, Susann M. Szmania, Junaid A. Khan, Antje Hoering, Paul A. Malbrough, Amberly Moreno-Bost, Amy D. Greenway, Joshuah D. Lingo, Xin Li, Shmuel Yaccoby, Larry J. Suva, Brian Storrie, Guido Tricot, Dario Campana, John D. Shaughnessy, Bijay P. Nair, William T. Bellamy, Joshua Epstein, Bart Barlogie, Frits van Rhee
Publikováno v:
Haematologica, Vol 97, Iss 9 (2012)
Background Patients with gene expression profiling-defined high-risk myeloma in relapse have poor outcomes with current therapies. We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound
Externí odkaz:
https://doaj.org/article/43e308d104fa406da5162d5351f878a6
Autor:
Amberly Moreno-Bost, Frits van Rhee, Giridhararao Jayandharan, Ramesh B. Batchu, Scott A. Gruber, Susann Szmania, Donald W. Weaver, Oksana V. Gruzdyn, Arun Srivastava, Bala K. Kolli
Publikováno v:
Vaccine. 32:938-943
MAGE-A3 is highly expressed in epithelial ovarian cancer (EOC), making it a promising candidate for immunotherapy. We investigated whether dendritic cells (DCs) transduced with a rAAV-6 capsid mutant vector Y445F could elicit effective MAGE-A3-specif
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82badc2fe79746c516a67728eab58fa7
https://doi.org/10.1016/j.vaccine.2013.12.049
https://doi.org/10.1016/j.vaccine.2013.12.049
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
Autor:
Susann Szmania, Juan F. Vera, Dario Campana, Natalia Lapteva, Elaine Coustan-Smith, April G. Durett, Amberly Moreno-Bost, Minhtran C. Ngo, Jiali Sun, Leslie L. Huye, Adrian P. Gee, Jun Ando, Lisa Rollins, Frits Vanrhee, Cliona M. Rooney, Jian Fang, Zhuyong Mei, Tarun K. Garg, Varada Dandekar, Kimberley Jackson
Publikováno v:
Cytotherapy. 14:1131-1143
Interest in natural killer (NK) cell-based immunotherapy has resurged since new protocols for the purification and expansion of large numbers of clinical-grade cells have become available.We have successfully adapted a previously described NK expansi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee7f76f3c0b4608cbc05773776cd59f5
https://doi.org/10.3109/14653249.2012.700767
https://doi.org/10.3109/14653249.2012.700767
Autor:
H. Grant Prentice, Bart Barlogie, Antje Hoerring, Jackie Szymonifka, John D. Shaughnessy, Frits van Rhee, Amberly Moreno-Bost, Katie L. Stone, Tarun K. Garg, Susann Szmania
Publikováno v:
Cytotherapy. 13:618-628
Immunotherapy targeting MAGE-A3 in multiple myeloma (MM) could eradicate highly aggressive and proliferative clonal cell populations responsible for relapse. However, expression of many cancer-testis antigens, including MAGE-A3, can be heterogeneous,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30a3d55d06f38a0310346beeab43e0e1
https://doi.org/10.3109/14653249.2010.529893
https://doi.org/10.3109/14653249.2010.529893
Autor:
Junaid A. Khan, Antje Hoering, Amy D Greenway, Bart Barlogie, Joshuah D Lingo, Katie L. Stone, Dario Campana, Shmuel Yaccoby, Emily Woods, Amberly Moreno-Bost, Tarun K. Garg, Frits van Rhee, Bijay Nair, William T. Bellamy, Joshua Epstein, Susann Szmania
Publikováno v:
Blood. 118:2918-2918
Abstract 2918 Natural killer cells (NK) have the unique ability to kill target cells without priming. While their therapeutic potential against various malignancies is becoming more apparent, it has been restricted to the allogeneic setting; NK cells
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::af25b743a8ab76f66bac82f144be15cd
https://doi.org/10.1182/blood.v118.21.2918.2918
https://doi.org/10.1182/blood.v118.21.2918.2918
Autor:
Jumei Shi, John D. Shaughnessy, Shmuel Yaccoby, Tarun K. Garg, Paul Malbrough, Amberly Moreno-Bost, Dario Campana, Frits van Rhee, Susann Szmania, Katie L. Stone, Charles Ekworomadu, Bart Barlogie, Emily Woods
Publikováno v:
Blood. 114:953-953
Abstract 953 Recently developed culture conditions for expanding and activating natural killer (NK) cells may improve immunotherapeutic options for patients with multiple myeloma. We have previously shown that co-incubation of NK cells from multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3d63c0155964dfea046d1a67bffce2a4
https://doi.org/10.1182/blood.v114.22.953.953
https://doi.org/10.1182/blood.v114.22.953.953
Autor:
Bart Barlogie, John D. Shaughnessy, Susann Szmania, Tarun K. Garg, Katie L. Stone, Amberly Moreno-Bost, Jumei Shi, Frits van Rhee, H G Prentice
Publikováno v:
Blood. 112:3674-3674
Demethylating agents and histone deacetylase inhibitors (HDACi) are epigenetic modulators that can induce re-expression of tumor suppressor and cell cycle proteins that have been silenced through aberrant hypermethylation associated with tumoral tran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee34db145f7d3bd920146e32e0dfcce3
https://doi.org/10.1182/blood.v112.11.3674.3674
https://doi.org/10.1182/blood.v112.11.3674.3674
Autor:
John D. Shaughnessy, Bart Barlogie, Tarun K. Garg, Jumei Shi, Amberly Moreno-Bost, Katie L. Stone, Frits van Rhee, Priyangi A. Malaviarachchi, Dario Campana, Susann Szmania, Fenghuang Zhan, Guido Tricot
Publikováno v:
Blood. 112:2758-2758
Introduction: Immunotherapy with innately competent natural killer (NK) cells can potentially synergize with chemotherapy by eradicating chemo-refractory residual disease. We recently reported that killer immunoglobulin-like receptor (KIR)-ligand mis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4af4505b25ad78d5aa521c905aae7d33
https://doi.org/10.1182/blood.v112.11.2758.2758
https://doi.org/10.1182/blood.v112.11.2758.2758
Autor:
Jumei Shi, Dario Campana, Tarun K. Garg, Frits van Rhee, Paul Malbrough, Katie L. Stone, Amberly Moreno-Bost, Susann Szmania, Daniel E. H. Afar, Bart Barlogie
Publikováno v:
Blood. 112:3666-3666
Immune-based therapies may improve outcome for multiple myeloma (MM) by eradicating chemo-resistant disease. Our recent trial utilizing IL2 activated, killer immunoglobulin-like receptor-ligand mismatched NK cell transfusions from haplo-identical don
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::092b78caa0ade46a3bb865eacdfa2635
https://doi.org/10.1182/blood.v112.11.3666.3666
https://doi.org/10.1182/blood.v112.11.3666.3666